Oral administration of plumbagin is beneficial in in vivo models of Duchenne muscular dystrophy through control of redox signaling

Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease. Recently approved molecular/gene treatments do not solve the downstream inflammation-linked pathophysiological issues such that supportive therapies are required to improve therapeutic efficacy and patients' quality of l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Free radical biology & medicine 2024-11, Vol.225, p.193-207
Hauptverfasser: Cervia, Davide, Zecchini, Silvia, Pincigher, Luca, Roux-Biejat, Paulina, Zalambani, Chiara, Catalani, Elisabetta, Arcari, Alessandro, Del Quondam, Simona, Brunetti, Kashi, Ottria, Roberta, Casati, Sara, Vanetti, Claudia, Barbalace, Maria Cristina, Prata, Cecilia, Malaguti, Marco, Casati, Silvia Rosanna, Lociuro, Laura, Giovarelli, Matteo, Mocciaro, Emanuele, Falcone, Sestina, Fenizia, Claudio, Moscheni, Claudia, Hrelia, Silvana, De Palma, Clara, Clementi, Emilio, Perrotta, Cristiana
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease. Recently approved molecular/gene treatments do not solve the downstream inflammation-linked pathophysiological issues such that supportive therapies are required to improve therapeutic efficacy and patients' quality of life. Over the years, a plethora of bioactive natural compounds have been used for human healthcare. Among them, plumbagin, a plant-derived analog of vitamin K3, has shown interesting potential to counteract chronic inflammation with potential therapeutic significance. In this work we evaluated the effects of plumbagin on DMD by delivering it as an oral supplement within food to dystrophic mutant of the fruit fly Drosophila melanogaster and mdx mice. In both DMD models, plumbagin show no relevant adverse effect. In terms of efficacy plumbagin improved the climbing ability of the dystrophic flies and their muscle morphology also reducing oxidative stress in muscles. In mdx mice, plumbagin enhanced the running performance on the treadmill and the muscle strength along with muscle morphology. The molecular mechanism underpinning these actions was found to be the activation of nuclear factor erythroid 2-related factor 2 pathway, the re-establishment of redox homeostasis and the reduction of inflammation thus generating a more favorable environment for skeletal muscles regeneration after damage. Our data provide evidence that food supplementation with plumbagin modulates the main, evolutionary conserved, mechanistic pathophysiological hallmarks of dystrophy, thus improving muscle function in vivo; the use of plumbagin as a therapeutic in humans should thus be explored further. [Display omitted] •Diet administered plumbagin regulates redox homeostasis in skeletal muscles of dystrophic animals.•Diet administered plumbagin decreases muscle damage of dystrophic flies and improves climbing ability.•Diet administered plumbagin reduces muscle damage, fibrosis and inflammation of dystrophic mice and improves their muscle function.
ISSN:0891-5849
1873-4596
1873-4596
DOI:10.1016/j.freeradbiomed.2024.09.037